{ "schemaVersion": "2.1", "datasetVersion": "2026-09-11.1", "generatedAt": "2026-09-11", "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.", "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.", "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.", "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.", "changeLogPath": "/corrections#correction-ledger", "contactPath": "/corrections", "dataset": "peptide-evidence-checker-record", "canonicalPath": "/peptides/cjc-1295", "canonicalUrl": "https://thepeptidefield.com/peptides/cjc-1295", "record": { "slug": "cjc-1295", "name": "CJC-1295", "className": "Long-acting version of a body signal that tells the body to release growth hormone", "sequenceLabel": "Modified peptide · different forms discussed", "tier": "Emerging", "statusLine": "Still being studied. This review found no FDA-approved CJC-1295 product in the United States.", "profile": { "humanOutcomes": { "level": "Limited", "note": "Studies in people measured hormone levels. They did not test lasting health benefits." }, "humanPharmacology": { "level": "Moderate", "note": "Short studies in healthy adults found that CJC-1295 raised growth hormone and insulin-like growth factor 1 (IGF-1) for a time." }, "safetyKnowledge": { "level": "Limited", "note": "The studies were short. FDA reports serious unwanted events, limited clinical data, and concerns about unwanted material in peptide products." }, "productCertainty": { "level": "Unclear", "note": "Online pages may use the name CJC-1295 for versions with DAC, without DAC, different salt forms, or mixtures with other ingredients." } }, "oneLine": "Short studies in healthy adults found that CJC-1295 raised growth hormone (GH) and insulin-like growth factor 1 (IGF-1). These hormone measurements do not prove better recovery, muscle gain, or fat loss.", "reviewedAt": "August 2, 2026", "whatItIs": "Growth hormone-releasing hormone is a body signal. It tells the body to release growth hormone. CJC-1295 is a changed version made to last longer. Online pages may use the name CJC-1295 for different forms. Some have a chemical part called DAC, and some do not.", "whatWeKnow": "Two studies assigned healthy adults to groups by chance. Some received CJC-1295, and some received a placebo, an inactive comparison. The studies found that growth hormone and IGF-1 stayed higher for a time. Another study found changes in how growth hormone was released. These studies measured body signals, not health benefits.", "whatWeDoNotKnow": "Higher hormone levels do not prove less body fat, more muscle, better recovery, better sleep, more energy, or a longer life. These studies did not establish those popular claims. Long-term safety is still unclear.", "safetyBoundary": "FDA says compounded CJC-1295 may pose a risk of unwanted immune reactions when given by certain routes. FDA also describes possible quality concerns, including peptide impurities and incomplete information about the active ingredient. FDA reports serious events associated with CJC-1295, including a faster heart rate and a whole-body reaction in which blood vessels widen. The small published studies did not report those serious events. Available clinical data are limited. This guide gives no dose or personal-use instructions.", "claims": [ { "claim": "“CJC-1295 can raise GH and IGF-1 in healthy adults.”", "verdict": "Supported with scope", "explanation": "Studies in people found that both hormones stayed higher for a time. This is a change in body measurements, not proof of a health benefit.", "category": "Mechanism and biomarkers", "evidenceBasis": "Human pharmacology", "scope": "Short-term changes in GH and IGF-1 measured in the healthy adults studied.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/16352683/", "https://pubmed.ncbi.nlm.nih.gov/17018654/" ] }, { "claim": "“CJC-1295 builds muscle and burns fat in people.”", "verdict": "Not established", "explanation": "The cited studies did not test lasting changes in body fat, muscle, or what people could do physically.", "category": "Performance and recovery", "evidenceBasis": "No reliable human outcome evidence", "scope": "Lasting changes in body fat, muscle, or what people could do physically. The cited hormone studies did not test these outcomes.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/16352683/", "https://pubmed.ncbi.nlm.nih.gov/17018654/" ] }, { "claim": "“All products called CJC-1295 are interchangeable.”", "verdict": "Misleading", "explanation": "Research papers and sellers may use the name for different forms, including different salts, changed versions, or mixtures with other ingredients.", "category": "Product equivalence", "evidenceBasis": "Regulatory or product record", "scope": "Products labeled CJC-1295 that differ in form, salt, chemical changes, added ingredients, or quality controls.", "sourceUrls": [ "https://www.fda.gov/media/183819/download", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" ] } ], "sources": [ { "label": "Prolonged GH and IGF-1 stimulation by CJC-1295 in healthy adults", "publisher": "PubMed · Journal of Clinical Endocrinology & Metabolism", "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/", "kind": "Randomized trial", "year": 2006, "accessedAt": "2026-07-23" }, { "label": "Pulsatile GH secretion during continuous stimulation by CJC-1295", "publisher": "PubMed · Journal of Clinical Endocrinology & Metabolism", "url": "https://pubmed.ncbi.nlm.nih.gov/17018654/", "kind": "Human pharmacology", "year": 2006, "accessedAt": "2026-07-23" }, { "label": "Certain bulk drug substances that may present significant safety risks", "publisher": "U.S. Food and Drug Administration", "url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "kind": "Regulatory", "year": 2026, "accessedAt": "2026-07-23" }, { "label": "CJC-1295 pharmacy compounding advisory review", "publisher": "U.S. Food and Drug Administration", "url": "https://www.fda.gov/media/183819/download", "kind": "FDA review", "year": 2024, "accessedAt": "2026-07-23" }, { "label": "2026 prohibited list", "publisher": "World Anti-Doping Agency", "url": "https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list", "kind": "Anti-doping", "year": 2026, "accessedAt": "2026-07-23" } ], "aliases": [ "CJC 1295", "CJC-1295 DAC", "CJC-1295 with DAC" ], "family": "Growth signaling", "evidenceContext": "Human pharmacology only", "productContext": "Some products use the name CJC-1295 for different chemical forms, including different salts. Some have a chemical part called DAC, and some do not. FDA says evidence for the DAC form cannot prove the same effects for a no-DAC form. These products are not automatically the same as modified GRF 1-29 or pharmacy-made mixtures with other ingredients.", "approvedProducts": [], "productRecords": [], "indications": [ "No FDA-approved indication" ], "reviewedAtISO": "2026-08-02", "reviewHistory": [ { "date": "2026-08-02", "note": "Clarified the human hormone findings, product-form limits, FDA safety record, and 2026 anti-doping status." }, { "date": "2026-07-23", "note": "Expanded alias, product-identity, and anti-doping context." } ], "antiDoping": "The 2026 World Anti-Doping Agency (WADA) list names CJC-1295 as a growth hormone-releasing hormone analogue. It is prohibited at all times for athletes covered by the list.", "antiDopingReview": { "status": "Prohibited", "detail": "The 2026 WADA list names CJC-1295 as a growth hormone-releasing hormone analogue. It is prohibited at all times for athletes covered by the list.", "sourceUrl": "https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list", "reviewedAtISO": "2026-08-02" }, "relatedSlugs": [ "tesamorelin", "sermorelin", "ipamorelin" ] } }